The Ocular Laboratory for Analysis of Biomarkers (OCULAB) program, launched by ARPA-H, focuses on advancing continuous biomarker monitoring through innovative tear-based diagnostic technology. Traditional methods of assessing biomarkers rely on invasive blood or urine tests, offering only a snapshot of health at a single time point. This limitation complicates disease monitoring, treatment adjustments, and precise dosing, requiring repeat clinic visits and laboratory tests. OCULAB aims to overcome these challenges by leveraging tears, which provide non-invasive, readily accessible biomarkers that reflect broader health dynamics.
OCULAB targets its initial efforts on Dry Eye Disease (DED), a prevalent condition affecting at least 20 million Americans, primarily women. DED, characterized by discomfort and vision problems, currently requires repeated doctor visits and laboratory tests for diagnosis and treatment adjustments. The program's vision includes a wearable nanosensor for continuous tear biomarker monitoring and a closed-loop system for personalized medication dosing. Tears offer advantages over blood and urine for continuous monitoring due to their water-based composition, reducing risks to delicate sensors while allowing precise hormone, protein, and vitamin measurement.
The program is structured around two primary technical objectives: developing nanosensors for tear duct implantation and integrating closed-loop therapeutic dosing systems. While DED is the initial focus, the OCULAB platform holds potential applications for other conditions, including hormonal, inflammatory, and ophthalmological disorders. By incorporating advancements in wearable technology, bioassays, nanotechnology, and AI algorithms, the program seeks to revolutionize health monitoring and treatment personalization.
OCULAB actively encourages collaboration among teams with diverse technical expertise to develop innovative solutions. Prospective participants can attend the hybrid Proposers' Day on December 12, 2024, in Tampa, Florida, to gain insights into the program's objectives and requirements. A teaming page is also available to facilitate partnerships and profile sharing among interested parties.
Solution summaries for the OCULAB program must be submitted by January 27, 2025, at 5:00 PM ET. Applicants are expected to propose solutions that align with OCULAB’s mission to develop continuous tear-based monitoring systems and personalized dosing technologies. Submissions will be evaluated based on innovation, feasibility, and potential impact on health diagnostics and treatment.
Through OCULAB, ARPA-H aims to bridge the gap in continuous biomarker monitoring, offering a new paradigm for disease management and personalized care. By bringing together multidisciplinary expertise and cutting-edge technology, the program aspires to deliver transformative solutions that improve patient outcomes and advance the field of precision medicine.
